Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levonorgestrel-releasing intrauterine system - Bayer

Next Previous
Drug Profile

Levonorgestrel-releasing intrauterine system - Bayer

Alternative Names: Kyleena; LNG-IUS 12

Latest Information Update: 02 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 05 Aug 2022 Bayer completes a phase III trial in Pregnancy (Prevention) in Russia (Intrauterine) (NCT03074045)
  • 22 Feb 2022 No development reported - Phase-III for Pregnancy (Prevention) in Mexico, Argentina, Chile, Finland, France, Hungary, Netherlands, Sweden (Intrauterine)
  • 04 Feb 2019 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top